Clinical trials: Papilloma Virus, Human
Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Randomized, 2-arm observational study. The 2 arms (randomized at the level of health care provider) will be: 1. usual practice; 2.
- Conditions
- Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Human Papilloma Virus Infection Type 6
- Trial name
- NCT02558803
- Testing
- Simple Reminder
- Where
- 5 sites in United States
- Volunteers
- 1,305 people
- Sponsor
- Regenstrief Institute, Inc.
Human Papillomavirus
Safety and Tolerability of GX-I7 in HPV-infected Female Volunteers
This is a phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety and tolerability of GX-I7 in HPV-infected female volunteers
- Trial name
- NCT03144934
- Testing
- GX-I7
- Where
- 4 sites in South Korea
- Volunteers
- 32 people
- Sponsor
- Genexine, Inc.
Human Papilloma Virus, Anogenital Wart
Human Papilloma Virus Genotypes and Treatment Outcomes of Intralesional Immunotherapy of Anogenital Warts
This study aims to investigate the relationship between HPV genotypes and treatment outcomes of intralesional immunotherapy of anogenital warts with the quadrivalent vaccine (Gardasil).
- Trial name
- NCT05761002
- Testing
- the Quadrivalent Vaccine (Gardasil)
- Where
- Egypt
- Volunteers
- 58 people
- Sponsor
- Zagazig University
Human Papillomavirus (HPV), Awareness and Knowledge Level
Effect of HPV Education on Women's Knowledge
This interventional study aims to evaluate the effectiveness of an educational program on women's knowledge of Human Papillomavirus (HPV), HPV vaccination, and screening.
- Trial name
- NCT07231263
- Testing
- HPV Awareness Education Group
- Where
- Turkey (Türkiye)
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Kahramanmaras Sutcu Imam University
Infections, Papillomavirus
Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. The current study is designed to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV vaccine…
- Trial name
- NCT00586339
- Testing
- Cervarix
- Where
- South Africa
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Recurrent Respiratory Papillomatosis
Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients
This research study is evaluating an immune modulatory agent as a possible treatment for patients with Recurrent Respiratory Papillomatosis (RRP) with significant disease involving the larynx, trachea, and/or lungs.
- Trial name
- NCT02632344
- Testing
- Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital
Infections, Papillomavirus
Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age
Human papillomavirus (HPV) infection has been established as a necessary cause of cervical cancer. GSK Biologicals has developed an HPV vaccine (580299) which targets the 2 most common oncogenic HPV types (HPV-16 and HPV-18)…
- Trial name
- NCT00492544
- Testing
- Cervarix™ (HPV-16/18 L1 VLP AS04)
- Where
- 5 sites in Japan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Advanced Cervical Adenocarcinoma, Advanced Vaginal Carcinoma
Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers
This phase I trial studies how well stereotactic body radiation therapy works in combination with tremelimumab and durvalumab in treating participants with cervical, vaginal, or vulvar cancers that have come back (recurrent) or…
- Conditions
- Advanced Cervical Adenocarcinoma, Advanced Vaginal Carcinoma, Advanced Vulvar Carcinoma, Human Papillomavirus-Related Cervical Squamous Cell Carcinoma
- Trial name
- NCT03452332
- Testing
- Durvalumab, Laboratory Biomarker Analysis, Stereotactic Radiosurgery
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Squamous Cell Carcinoma (HNSCC)
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks like a treatment but does not…
- Trial name
- NCT06769698
- Testing
- FDC fianlimab+cemiplimab, Cemiplimab
- Where
- 38 sites in United States, Australia and 4 more
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Head and Neck Cancer, Oropharyngeal Cancer
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy
The purpose of this study is to investigate the role of the immune system in the response of squamous cell cancers of the head and neck to treatment that includes radiation therapy.
- Conditions
- Head and Neck Cancer, Oropharyngeal Cancer, Human Papillomavirus, Squamous Cell Cancer
- Trial name
- NCT01358097
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Cervical Cancer
Acceptability of Human Papillomavirus (HPV) Self-sampling Tools for Cervical Cancer Prevention
The proposed study aims to increase HPV screening behaviors in Jamaican women by examining the acceptability of HPV Deoxyribonucleic Acid (DNA) self-sampling tools, and to determine the most culturally appropriate and effective…
- Trial name
- NCT03613493
- Testing
- HPV self-sampling kit, Culturally-targeted Fear Appeal Message, Fear Appeal Message
- Where
- United States
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- University of Miami
Genital Infection Viral, HUMAN PAPILLOMA VIRUS
Phase II Study of HPV Therapeutic Vaccine in HPV Infected Women With Normal Cytology or ASCUS/LSIL
Human Papillomavirus (HPV) 16 and HPV 18 (the two virus genotypes targeted by the ProCervix vaccine) are the most common HPV genotypes associated with at least 70% of squamous cell carcinomas and 82% of adenocarcinomas of the…
- Trial name
- RHEIA-VAC (NCT01957878)
- Testing
- ProCervix
- Where
- 40 sites in Belgium, Finland and 5 more
- Volunteers
- 239 people
- Sponsor
- Genticel
HIV Infections, Human Papillomavirus Infection
Screening for HPV and Cervical Cancer in Young Women With Perinatally Acquired HIV
This is a cross-sectional, observational study of high-risk HPV status, cervical cytology and HPV vaccine uptake and response in young women with perinatally acquired HIV.
- Conditions
- HIV Infections, Human Papillomavirus Infection, Cervical Cancer
- Trial name
- SHiP (NCT04587050)
- Testing
- Human papillomavirus testing, Cervical cytology, HPV serology
- Where
- United Kingdom
- Volunteers
- 57 people
- Sponsor
- Imperial College London
Human Papilloma Virus
Prevention of Cervical Cancer Using the Genotyping Screening and Same-day Self-sampling
In May 2018, the World Health Organization (WHO) launched a strategy to eliminate cervical cancer. While this strategy seeks to achieve coverage of 70% in disease testing and 90% in treatment by 2030, it is estimated that these…
- Trial name
- PROGRESS (NCT07232355)
- Where
- 4 sites in United States, El Salvador and 1 more
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Atila Biosystems Inc.
Infections, Papillomavirus
Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study
This extension study is designed to assess the safety of GSK Biological's human papillomavirus (HPV) vaccine GSK580299 in female subjects who took part in the primary study NCT00294047 and received the control vaccine in…
- Trial name
- NCT01190189
- Testing
- GSK580299 (Cervarix)
- Where
- 28 sites in United States, Canada
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papilloma Virus
Promoting Human Papillomavirus (HPV) Vaccination Through African American Beauty Salons
The investigators propose a non-randomized pilot study to assess the feasibility and effectiveness of using urban beauty salons as settings for culturally-competent health education about HPV vaccination.
- Trial name
- NCT01461408
- Testing
- Health Education Session
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- MEE Productions, Inc.
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.
HPV-related Lower Genital Tract Neoplasias, HPV-related Anal Neoplasias
Screening Women With Prior HPV for Anal Neoplasia
The goal of this single arm trial is to prospectively evaluate screening methods for anal cancer precursors in HIV uninfected women with a history of lower genital tract neoplasias and cancers.
- Conditions
- HPV-related Lower Genital Tract Neoplasias, HPV-related Anal Neoplasias, Early Stage Lower Genital Tract Cancers
- Trial name
- SWAN (NCT05217940)
- Testing
- Diagnostic tests for anal cancer screening
- Where
- 3 sites in United States
- Volunteers
- 300 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Cervical Cancer, Cancer
A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer
This was a multicenter, open-label, 2-part randomized study of MEDI4736 administered as monotherapy or in combination with ADXS11-001 to participants with recurrent/persistent or metastatic squamous or non-squamous carcinoma of…
- Conditions
- Cervical Cancer, Cancer, Head and Neck Cancer
- Trial name
- NCT02291055
- Testing
- ADXS11-001, MEDI4736
- Where
- 17 sites in United States
- Volunteers
- 75 people
- Sponsor
- Advaxis, Inc.
Cervical Cancer
HPV Self-test to Increase Cervical Cancer Screening in Asian Women
The study was to pilot test the feability of using HPV self-sampling testing to increase cervical cancer screening among under-served Asian women through engaging community-based organizations in the greater Philadelphia and New…
- Trial name
- NCT04612660
- Testing
- Education on cervical cancer prevetnion, Dynamic group interaction, Physician engagement
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- Temple University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.